The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Prodrug Platin‐A: Simultaneous Release of Cisplatin and Aspirin
Abstract
Cancer‐associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo‐anti‐inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin‐A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin‐A exhibited anticancer and anti‐inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti‐inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Self-citationAcid-Mediated Tumor Invasion: a Multidisciplinary Study
Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B., & Gillies, R. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4193 · Cited by 771
Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation
Grilli, M., Pizzi, M., Memo, M., & Spano, P. (1996) · Science · doi:10.1126/science.274.5291.1383 · Cited by 750
Redox activation of metal-based prodrugs as a strategy for drug delivery
Graf, N., & Lippard, S. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.007 · Cited by 523
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
Denmeade, S. R., Lin, X. S., & Isaacs, J. T. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199604)28:4<251::aid-pros6>3.0.co;2-g · Cited by 436
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. B. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0022-y · Cited by 319
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
OH, W. K., & KANTOFF, P. W. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62501-1 · Cited by 260
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Cyclooxygenase-2 and prostate carcinogenesis
Hussain, T., Gupta, S., & Mukhtar, H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00524-4 · Cited by 237
So, H., Kim, H., Lee, J.-H., Park, C., Kim, Y., Kim, E., Kim, J.-K., Yun, K.-J., Lee, K.-M., Lee, H.-Y., et al. (2007) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-007-0084-9 · Cited by 230
Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171
Marrache, S., Tundup, S., Harn, D. A., & Dhar, S. (2013) · ACS Nano · doi:10.1021/nn403158n · Cited by 144
Self-citationSubbarayan, V., Sabichi, A. L., Llansa, N., Lippman, S. M., & Menter, D. G. (2001) · PubMed · Cited by 115
Oeth, P., & Mackman, N. (1995) · Blood · doi:10.1182/blood.v86.11.4144.bloodjournal86114144 · Cited by 85
Mechanistic Insights into Cyclooxygenase Irreversible Inactivation by Aspirin
Tosco, P., & Lazzarato, L. (2009) · ChemMedChem · doi:10.1002/cmdc.200800438 · Cited by 36
Mehar, A., Macanas-Pirard, P., Mizokami, A., Takahashi, Y., Kass, G. E. N., & Coley, H. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131383 · Cited by 28
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Platinum(iv) anticancer prodrugs – hypotheses and facts
Gibson, D. (2016) · Dalton Transactions · doi:10.1039/c6dt01414c · Cited by 286
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Metadata
- Authors
- Pathak, R. K., Marrache, S., Choi, J. H., Berding, T. B., & Dhar, S.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-01-22
- Volume
- 53
- Issue
- 7
- Pages
- 1963-1967
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2114410648
- Cited by
- 255
- References
- 30
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.